These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 2466548)

  • 1. Chemotherapy of invasive thymoma. A retrospective study of 22 cases.
    Göldel N; Böning L; Fredrik A; Hölzel D; Hartenstein R; Wilmanns W
    Cancer; 1989 Apr; 63(8):1493-500. PubMed ID: 2466548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymoma. A retrospective study of 87 cases.
    Park HS; Shin DM; Lee JS; Komaki R; Pollack A; Putnam JB; Cox JD; Hong WK
    Cancer; 1994 May; 73(10):2491-8. PubMed ID: 8174044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
    Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
    N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
    Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
    Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
    Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
    J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Invasive thymoma with pulmonary metastasis. Complete remission 5 years after surgery and chemotherapy using the CHOP-BLEO protocol].
    Wurtz A; Ramon P; Chambon JP; Wallaert B; Gosselin B
    Rev Mal Respir; 1988; 5(6):651-4. PubMed ID: 2464185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy for invasive thymoma. A 13-year experience.
    Fornasiero A; Daniele O; Ghiotto C; Piazza M; Fiore-Donati L; Calabró F; Rea F; Fiorentino MV
    Cancer; 1991 Jul; 68(1):30-3. PubMed ID: 2049749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of conventional chemotherapy in aggressive lymphomas.
    Cunningham D; Hepplestone A; Gilchrist NL; Dagg JH; Evans IL; Soukop M
    Postgrad Med J; 1987 Jan; 63(735):11-5. PubMed ID: 2444960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
    Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M
    Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of invasive thymoma.
    Fornasiero A; Daniele O; Ghiotto C; Sartori F; Rea F; Piazza M; Fiore-Donati L; Morandi P; Aversa SM; Paccagnella A
    J Clin Oncol; 1990 Aug; 8(8):1419-23. PubMed ID: 2380761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of malignant thymoma. Case report and review of the literature.
    Hu E; Levine J
    Cancer; 1986 Mar; 57(6):1101-4. PubMed ID: 3080220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report.
    Kim ES; Putnam JB; Komaki R; Walsh GL; Ro JY; Shin HJ; Truong M; Moon H; Swisher SG; Fossella FV; Khuri FR; Hong WK; Shin DM
    Lung Cancer; 2004 Jun; 44(3):369-79. PubMed ID: 15140551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease.
    Fuchs R; Löffler M; Pfreundschuh M; Dölken G; Gerhartz H; Hagen-Aukamp U; Hiller E; Petsch S; Pflüger KH; Rühl U
    Leuk Lymphoma; 1994 Jun; 14(1-2):79-89. PubMed ID: 7522721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
    Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
    J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
    Aleman BM; Raemaekers JM; Tomiŝiĉ R; Baaijens MH; Bortolus R; Lybeert ML; van der Maazen RW; Girinsky T; Demeestere G; Lugtenburg P; Lievens Y; de Jong D; Pinna A; Henry-Amar M;
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):19-30. PubMed ID: 17097834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.
    Loehrer PJ; Kim K; Aisner SC; Livingston R; Einhorn LH; Johnson D; Blum R
    J Clin Oncol; 1994 Jun; 12(6):1164-8. PubMed ID: 8201378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.